H. Elokdah

发表

Mapping of a Conformational Epitope on Plasminogen Activator Inhibitor-1 by Random Mutagenesis

D. L. Crandall, K. Fan, N. Gorlatova, 2003, The Journal of Biological Chemistry.

Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis

H. Elokdah, G. Friedrichs, A. Ji, 2005, Journal of Pharmacology and Experimental Therapeutics.

Characterization and comparative evaluation of a structurally unique PAI‐1 inhibitor exhibiting oral in‐vivo efficacy

N. Gorlatova, D. Lawrence, H. Elokdah, 2004, Journal of thrombosis and haemostasis : JTH.

WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation.

J. Bauer, G. Krishnamurthy, H. Elokdah, 2003, Biochemical and biophysical research communications.

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization.

G. Krishnamurthy, M. Abou-Gharbia, H. Elokdah, 2004, Journal of medicinal chemistry.

Design and synthesis of tricyclic derivatives as high density lipoprotein cholesterol enhancers.

H. Elokdah, S. Chai, D. Ho, 2001, Bioorganic & medicinal chemistry letters.

Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling

D. Vaughan, N. Brown, A. Fogo, 2004, Arteriosclerosis, thrombosis, and vascular biology.

Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.

K. Washington, M. Eren, D. Vaughan, 2006, Blood.

Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis

T. Wakefield, R. Schaub, Thomas R Meier, 2008, Thrombosis and Haemostasis.

Regioselective Suzuki coupling of benzofuran or benzothiophene boronic acids and dibromo substituted naphthalenes: synthesis of a potent inhibitor of plasminogen activator inhibitor-1

H. Elokdah, Z. Wang, G. Mcfarlane, 2006 .

Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects.

B. Harrison, H. Elokdah, G. Friedrichs, 2002, Bioorganic & medicinal chemistry letters.

Neutralization of Plasminogen Activator Inhibitor I (PAI-1) by the Synthetic Antagonist PAI-749 via a Dual Mechanism of Action

S. Gardell, S. Mayer, H. Elokdah, 2007, Molecular Pharmacology.

Efficient One-Pot Synthesis of Substituted 2-Amino-1,3,4-oxadiazoles.

H. Elokdah, J. Butera, E. Chekler, 2008 .

Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonists.

A. Robichaud, R. Magolda, H. Elokdah, 2007, Bioorganic & medicinal chemistry.

Design, synthesis, and biological evaluation of thio-containing compounds with serum HDL-cholesterol-elevating properties.

M. Abou-Gharbia, H. Elokdah, M. McKean, 2004, Journal of medicinal chemistry.

Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade

T. Comery, A. Robichaud, M. Pangalos, 2008, Proceedings of the National Academy of Sciences.

Mechanism of Inactivation of Plasminogen Activator Inhibitor-1 by a Small Molecule Inhibitor*

K. Fan, N. Gorlatova, D. Lawrence, 2007, Journal of Biological Chemistry.

Efficient One-Pot Synthesis of Substituted 2-Amino-1,3,4-oxadiazoles.

H. Elokdah, J. Butera, E. Chekler, 2009 .

Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling

D. Vaughan, N. Brown, A. Fogo, 2004, Arteriosclerosis, thrombosis, and vascular biology.